Login / Signup

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Sarina A Piha-PaulChristine L HannChristopher A FrenchSophie CousinIrene BrañaPhillippe A CassierVictor MorenoJohann S de BonoSara Duckworth HarwardGeraldine Ferron-BradyOlena BarbashAnastasia WyceYuehui WuThierry HornerMeg AnnanNigel J ParrRabinder K PrinjhaChristopher L CarpenterJohn HiltonDavid S HongNaomi B HaasMark C MarkowskiArindam DharPeter J O'DwyerGeoffrey I Shapiro
Published in: JNCI cancer spectrum (2019)
Once-daily molibresib was tolerated at doses demonstrating target engagement. Preliminary data indicate proof-of-concept in NC.
Keyphrases
  • electronic health record
  • open label
  • social media
  • signaling pathway
  • physical activity
  • big data
  • pi k akt
  • protein protein
  • amino acid
  • binding protein
  • double blind
  • small molecule